Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07612878
Recruiting Observational

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

NCT07612878 · tracked via the Priya Life Science USA tracker
Sponsor
Sanofi
Phase
Observational
Started
2026-08-06
Last updated
2026-10-15

Condition(s) studied

COPD (Chronic Obstructive Pulmonary Disease)

Investigational drug(s) / intervention(s)

Cohort 1: Dupilumab →Cohort 2: usual care only

Cohort 1: Dupilumab: medicine already approved by the FDA

Cohort 2: usual care only: Usual care that patients receive

Study summary

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * COPD patients who are newly referred to start dupilumab treatment * Age ≥ 40 years * Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit Exclusion Criteria: * Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI) * Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments * Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Primary outcome measure(s)

  • Participant Characteristics — End of study (24 months after the last participant is enrolled)
    Age
  • Participant Characteristics — End of study (24 months after the last participant is enrolled)
    Sex
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Height in meters
  • Participant Characteristics — End of study (24 months after the last participant is enrolled)
    Weight in kilograms
  • Patients Characteristics — End of study (24 months after the last participant is enrolled)
    BMI in kg/m\^2
  • Patients Characteristics — End of study (24 months after the last participant is enrolled)
    Smoking and cannabis status/type/history
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Medical History
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Baseline disease characteristics
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Emphysema status
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Disease severity
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Eosinophil value
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    COPD-relevant vaccination status
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Prior and current medications
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Previous and current comorbidities
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Reason(s) for initiation of dupilumab treatment
  • Patient Characteristics — End of study (24 months after the last participant is enrolled)
    Insurance Provider

Trial sites (7)

FacilityCityRegionStatus
IU Health Pulmonology & Critical Care Medicine Indianapolis Indiana Recruiting
University of Kansas Lawrence Kansas Recruiting
Duke Durham North Carolina Recruiting
Ohio State University Columbus Ohio Recruiting
The Respire Institute Houston Texas Recruiting
Activian Clinical Research Kingwood Texas Recruiting
The Lung & Sleep Institute of North Texas North Richland Hills Texas Recruiting

More Sanofi trials in the USA

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration Active, not recruiting
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials Active, not recruiting
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis Active, not recruiting
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 Active, not recruiting

Other trials for the same condition

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) Recruiting
COPD Exacerbation Follow Up Recruiting
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD Active, not recruiting
MoblO2 to Maintain Oxygenation Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07612878 on ClinicalTrials.gov ↗ ← All trials in the USA